JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on Advanced Drug Delivery Systems Using 3D-Printed Biodegradable Polymers

Ramprasad D. Kadam*[1], Amol S. Rakte[2], Mangesh M. Galbale[1], Swaraj S. Warkad[1]

[1] *Research Scholar, Department of Pharmaceutics, IVM's Krishnarao Bhegade Institute of Pharmaceutical Education and Research, Talegaon Dabhade, Maharashtra, India*
[2] *Professor and HOD, Department of Pharmaceutics, IVM's Krishnarao Bhegade Institute of Pharmaceutical Education and Research, Talegaon Dabhade, Maharashtra, India*

Publication history: Received on 25th Mar 2025; Revised on 17th April 2025; Accepted on 21st April 2025

Article DOI: 10.69613/2q6qdy97

Abstract: Three-dimensional (3D) printing technology combined with biodegradable polymers enables the development of patient-specific drug formulations with improved therapeutic outcomes. Biodegradable polymers like polylactic acid (PLA), polycaprolactone (PCL), and poly(lactic-co-glycolic acid) (PLGA) serve as primary materials in pharmaceutical 3D printing due to their tunable degradation profiles and biocompatibility. Recent trends include the incorporation of nanoparticles within polymer matrices, development of hybrid biomaterial composites, and integration of artificial intelligence for optimizing printing parameters. The emergence of smart polymers and 4D printing has enabled the creation of stimuli-responsive drug delivery systems that can adapt to physiological conditions. The integration of Internet of Things (IoT) technology with 3D-printed devices facilitates real-time monitoring and remote drug customization. However, several challenges are yet to be overcome, including regulatory compliance, scalability limitations, and the need for precise control over polymer degradation kinetics. Ongoing research focuses on developing environmentally sustainable polymers, improving printability, and optimizing material properties for enhanced therapeutic efficacy. The potential for localized drug manufacturing at pharmacies and the creation of patient-specific implants highlights the transformative impact of this technology on healthcare delivery. The current limitations can be overcome with continued research and interdisciplinary collaboration which will accelerate the clinical implementation of 3D-printed biodegradable polymers in personalized medicine.

Keywords: Biodegradable polymers; Drug delivery systems; Personalized medicine; Smart polymers; 3D bioprinting.

1. Introduction

The evolution of personalized medicine has transformed traditional healthcare approaches by customizing therapeutic interventions to individual patient needs. The integration of advanced materials and fabrication technologies, particularly three-dimensional (3D) printing with biodegradable polymers, has emerged as a pivotal development in creating patient-specific drug delivery systems [1, 2]. Biodegradable polymers play an essential role in modern drug delivery applications due to their ability to degrade into non-toxic byproducts that can be easily metabolized and eliminated from the body [3]. Among these, poly(lactic-co-glycolic acid) (PLGA) has garnered significant attention due to its versatile degradation profile, which can be modified by altering molecular weight and copolymer ratios [4]. Research has demonstrated the effectiveness of PLGA-based nanocarriers in delivering chemotherapeutic agents directly to tumor sites, minimizing toxicity to healthy tissues [5].

Three-dimensional printing, also known as additive manufacturing, has revolutionized numerous sectors, including pharmaceutical development and healthcare delivery [6]. When combined with biodegradable polymers, this technology enables the creation of intricate structures with precise geometries, essential for controlled drug release and tissue regeneration [7]. For instance, 3D-printed PLGA scaffolds have demonstrated exceptional mechanical properties and biocompatibility in bone tissue engineering applications [8]. The customization capabilities of 3D printing technology have particular significance in drug delivery applications. This approach allows for the fabrication of implants and drug delivery devices tailored to individual patient anatomical and physiological requirements [9]. Recent developments include the incorporation of smart polymers that respond to physiological stimuli, enabling controlled drug release profiles [10]. The convergence of biodegradable polymers and 3D printing technology has led to significant innovations in personalized medicine. These include the development of patient-specific implants, controlled-release drug delivery systems, and smart devices that can adapt to physiological changes [11]. Additionally, the emergence of 4D printing technology, where printed structures can change shape or properties in response to environmental stimuli, opens new possibilities for dynamic drug delivery systems [12].

* Corresponding author: Ramprasad D. Kadam

Current research directions focus on optimizing polymer properties, improving printing precision, and developing novel composite materials that combine the benefits of multiple components [13]. The integration of artificial intelligence and machine learning algorithms has further enhanced the design and manufacturing processes of these systems [14]. Despite these advances, several challenges remain in the widespread implementation of 3D-printed biodegradable polymer systems. These include regulatory considerations, scaling limitations, and the need for comprehensive long-term safety studies [15]. Addressing these challenges requires continued research efforts and collaboration across multiple disciplines. This review describes about the biodegradable polymers, 3D printing technology, and personalized medicine. Various aspects like material selection to manufacturing processes and potential of these technologies to revolutionize healthcare delivery.



Figure 1. Parameters Involved in 3D Printed Drug Delivery Systems

2. 3D-Printed Biodegradable Polymers

2.1. Classification and Properties of Biodegradable Polymers

Biodegradable polymers utilized in 3D printing applications can be categorized into natural and synthetic origins. Natural biodegradable polymers, derived from renewable resources, include polysaccharides such as chitosan, alginate, and cellulose derivatives [16]. These materials exhibit inherent biocompatibility and contain functional groups that facilitate cell attachment and proliferation [17].

Table 1. Common Biodegradable Polymers Used in 3D-Printed Drug Delivery Systems

Polymer Type	Degradation Time	Processing Temperature (°C)	Applications	Advantages
PLA	12-24 months	180-220	Implants, Scaffolds	High mechanical strength
PLGA	1-6 months	160-200	Drug delivery devices	Tunable degradation
PCL	24-36 months	60-90	Tissue engineering	Low melting point
PVA	Hours to weeks	160-180	Oral medications	Water soluble
Chitosan	2-6 months	80-120	Wound dressings	Biocompatible

Synthetic biodegradable polymers, including poly(lactic acid) (PLA), poly(caprolactone) (PCL), and poly(lactic-co-glycolic acid) (PLGA), offer advantages such as controlled degradation rates and tunable mechanical properties [18]. The degradation mechanisms of these polymers primarily involve hydrolytic chain scission, resulting in the formation of biocompatible metabolites [19].

2.2. Material Selection Criteria

The selection of appropriate biodegradable polymers for 3D printing applications depends on several critical factors:

2.2.1. Thermal Properties

Thermal characteristics, including glass transition temperature (Tg) and melting temperature (Tm), significantly influence the printability and processing conditions. For fused deposition modeling (FDM), polymers must exhibit suitable melt flow properties while maintaining thermal stability during processing [20].



Figure 2. Development Pipeline for 3D Printed Drug Delivery Systems

2.2.2. Mechanical Properties

The mechanical strength and elasticity of printed structures must align with their intended applications. For instance, bone tissue engineering scaffolds require higher mechanical strength compared to soft tissue applications [21].

2.2.3. Degradation Kinetics

The degradation rate of the polymer matrix must match the therapeutic requirements and tissue regeneration timeline. Factors affecting degradation include molecular weight, crystallinity, and environmental conditions [22].

2.3. Polymer Processing and Modification

2.3.1. Surface Modification

Surface modification techniques enhance the functionality of biodegradable polymers. Plasma treatment, chemical grafting, and coating methods improve cell adhesion, drug loading capacity, and surface properties [23].

2.3.2. Composite Development

The incorporation of reinforcing materials, such as bioactive glass particles or hydroxyapatite, enhances the mechanical and biological properties of printed structures [24]. These composites often demonstrate superior performance compared to single-component systems.

2.4. Characterization Methods

Comprehensive characterization of 3D-printed biodegradable polymers involves multiple analytical techniques:

2.4.1. Physical Characterization

Techniques such as differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and X-ray diffraction (XRD) provide insights into thermal properties and crystalline structure [25].

2.4.2. Mechanical Testing

Compression, tensile, and flexural testing evaluate the mechanical performance of printed structures under various loading conditions [26].

2.4.3. Morphological Analysis

Scanning electron microscopy (SEM) and atomic force microscopy (AFM) reveal surface topography and internal architecture of printed constructs [27].

2.4.4. Degradation Studies

In vitro degradation studies assess mass loss, pH changes, and the release of degradation products under physiological conditions [28].

3. 3D Printing Techniques for Biodegradable Polymer-Based Drug Delivery

3.1. Fused Deposition Modeling (FDM)

FDM is a widely adopted technique for fabricating drug delivery systems using biodegradable polymers. The process involves the thermal extrusion of polymer filaments through a heated nozzle, depositing material layer by layer to create three-dimensional structures [29].

Table 2. 3D Printing Technologies for Pharmaceutical Applications

Technology	Resolution Range	Material Types	Drug Stability	Manufacturing Speed
FDM	100-300 μm	Thermoplastics	Medium	High
SLA	25-100 μm	Photopolymers	High	Medium
SLS	50-200 μm	Powder polymers	High	Low
Inkjet	50-100 μm	Solutions/Suspensions	Very High	Medium
Extrusion	200-400 μm	Hydrogels	High	Low

3.1.1. Process Parameters

Critical parameters affecting print quality include nozzle temperature, bed temperature, layer height, and print speed. These parameters must be optimized based on the polymer's thermal and rheological properties [30]. For instance, PLA typically requires nozzle temperatures between 180-220°C, while PCL processes at lower temperatures around 60-90°C [31].

3.1.2. Drug Loading Strategies

Drug incorporation in FDM can be achieved through various approaches:

- Hot-melt extrusion of drug-polymer mixtures to create pharmaceutical grade filaments
- Impregnation of printed structures with drug solutions
- Core-shell printing for sustained release applications [32]

Table 3. Drug Loading Methods and Their Characteristics

Method	Loading Efficiency	Process Complexity	Drug Stability	Scale-up Potential
Hot-melt mixing	70-90%	Medium	Low	High
Solvent casting	80-95%	High	High	Medium
Surface coating	60-80%	Low	Very High	High
Impregnation	40-70%	Medium	High	Medium
In-situ loading	85-95%	High	Medium	Low

3.2. Stereolithography (SLA)

SLA utilizes photopolymerization to create precise structures with high resolution, particularly beneficial for complex drug delivery devices [33].

3.2.1. Photocurable Resins

Development of biocompatible photocurable resins incorporating biodegradable elements enables the fabrication of drug-loaded structures. Modified PLA and PCL-based resins with photoinitiators demonstrate successful printing outcomes while maintaining drug stability [34].

3.2.2. Resolution and Surface Quality

SLA typically achieves higher resolution compared to FDM, with feature sizes as small as 50 micrometers. This precision enables the creation of intricate internal channels and surface patterns for controlled drug release [35].

3.3. Selective Laser Sintering (SLS)

SLS technology employs laser energy to selectively fuse polymer powder particles, creating complex structures with controlled porosity [36].

3.3.1. Powder Characteristics

Particle size distribution, flowability, and thermal properties significantly influence the printing process. Optimal powder characteristics typically include particle sizes between 45-90 micrometers and specific thermal properties that prevent premature fusion [37].

3.3.2. Process Optimization

Key parameters include laser power, scan speed, and powder bed temperature. These factors must be carefully controlled to achieve desired mechanical properties and drug stability [38].

3.4. Inkjet Printing

Inkjet printing technology offers precise control over drug distribution and dosage through droplet-based deposition [39].

3.4.1. Bio-ink Formulation

Development of printable solutions containing biodegradable polymers and active pharmaceutical ingredients requires careful consideration of viscosity, surface tension, and solidification mechanisms [40].

3.4.2. Multi-Material Printing

Advanced inkjet systems enable the simultaneous printing of multiple materials, allowing the creation of complex drug delivery systems with varying release profiles [41].

3.5. Microextrusion Bioprinting

This technique enables the continuous extrusion of polymer solutions or melts through fine nozzles, particularly suitable for hydrogel-based drug delivery systems [42].

3.5.1. Rheological Requirements

Bio-ink viscosity and shear-thinning behavior must be optimized to ensure consistent material flow and shape fidelity after deposition [43].

3.5.2. Environmental Conditions

Temperature, humidity, and crosslinking mechanisms play crucial roles in maintaining structural integrity and drug stability during the printing process [44].

4. Applications in Personalized Medicine

4.1. Patient-Specific Implants and Scaffolds

The integration of medical imaging data with 3D printing technology enables the creation of anatomically precise implants and scaffolds. These structures can be tailored to match individual patient anatomy while incorporating specific drug delivery requirements [45]. Advanced computational modeling assists in optimizing the mechanical properties and degradation profiles of these personalized implants, ensuring optimal therapeutic outcomes [46].

4.1.1. Bone Tissue Engineering

Three-dimensionally printed scaffolds incorporating calcium phosphate and biodegradable polymers demonstrate enhanced osteogenic properties. The precise control over pore size, distribution, and interconnectivity promotes cellular infiltration and vascularization, leading to improved bone regeneration outcomes [47]. Recent developments include the incorporation of growth factors within the polymer matrix, providing sustained release of bioactive molecules to guide tissue formation [48].

4.1.2. Soft Tissue Applications

For soft tissue reconstruction, flexible and elastomeric biodegradable polymers can be printed into structures that match tissue mechanical properties. These implants often incorporate anti-inflammatory drugs or growth factors to modulate the healing response and prevent complications [49].

4.2. Controlled Drug Release Systems

4.2.1. Oral Drug Delivery

Advanced 3D printing enables the fabrication of complex oral dosage forms with precise control over drug distribution and release kinetics. Multi-compartment tablets containing different drugs or release profiles can be created to optimize therapeutic efficacy and patient compliance [50]. The ability to modify tablet geometry and internal structure allows for customized release profiles based on individual patient needs [51].

4.2.2. Implantable Drug Delivery Devices

Biodegradable implants with controlled drug release capabilities offer advantages in maintaining therapeutic drug levels while minimizing systemic exposure. These devices can be designed with specific release durations, ranging from days to months, depending on the polymer composition and device architecture [52].

4.3. Transdermal Drug Delivery Systems

The fabrication of microneedle arrays using biodegradable polymers represents a significant advancement in transdermal drug delivery. These systems can be customized in terms of needle geometry, drug loading, and penetration depth to optimize delivery efficiency [53]. Recent innovations include stimulus-responsive microneedles that respond to specific biological triggers, enabling smart drug release [54].

4.4. Cancer Therapy Applications

4.4.1. Local Drug Delivery Systems

Three-dimensionally printed implants loaded with chemotherapeutic agents provide targeted drug delivery to tumor sites. These systems can incorporate multiple drugs with different release profiles, enabling combination therapy approaches [55]. The local delivery approach significantly reduces systemic toxicity while maintaining high drug concentrations at the tumor site [56].

4.4.2. Theranostic Devices

Integration of imaging agents within drug-loaded biodegradable implants enables simultaneous therapeutic delivery and monitoring of treatment response. These theranostic systems provide valuable information about drug distribution and therapeutic efficacy [57].

4.5. Smart Drug Delivery Systems

4.5.1. Stimulus-Responsive Materials

Advanced polymer systems incorporating smart materials respond to specific physiological triggers such as pH, temperature, or enzyme levels. These systems enable precise control over drug release based on pathological conditions [58].

4.5.2. Feedback-Controlled Release

Integration of biosensors with smart delivery systems enables real-time monitoring and adjustment of drug release rates. This approach ensures optimal therapeutic levels while minimizing adverse effects [59].



Figure 3. Drug Release Mechanisms from 3D Drug Delivery Systems

5. Current Trends and Recent Advances

5.1. Nanoparticles with 3D-Printed Polymers

Metallic nanoparticles, quantum dots, and carbon-based nanomaterials incorporated into biodegradable polymer matrices provide additional functionalities such as improved mechanical properties, antimicrobial activity, and controlled drug release [60]. Gold nanoparticles integrated within printed structures enable photothermal therapy applications, while magnetic nanoparticles facilitate targeted drug delivery through external magnetic fields [61].

5.2. Hybrid Biomaterial Composites

5.2.1. Natural-Synthetic Polymer Blends

Novel combinations of natural and synthetic polymers yield materials with enhanced biological and mechanical properties. For instance, PCL-collagen composites demonstrate improved cell adhesion while maintaining structural integrity [62]. These hybrid systems often exhibit synergistic effects, combining the processability of synthetic polymers with the bioactivity of natural materials [63].

5.2.2. Ceramic-Polymer Composites

The incorporation of bioactive ceramics such as hydroxyapatite and tricalcium phosphate into polymer matrices enhances osteoconductivity and mechanical strength. Recent advances include gradient structures that better mimic natural tissue interfaces [64].

5.3. Artificial Intelligence in 3D Printing

5.3.1. Design Optimization

Machine learning algorithms optimize printing parameters and predict material behavior during processing. These tools enable rapid development of new formulations and reduce the time required for optimization studies [65].

5.3.2. Quality Control Systems

AI-powered monitoring systems analyze printing processes in real-time, detecting defects and adjusting parameters to maintain print quality. Computer vision systems evaluate printed structures for consistency and compliance with design specifications [66].

5.4. 4D Printing Applications

5.4.1. Shape Memory Systems

Advanced polymer systems capable of shape transformation in response to environmental stimuli enable novel therapeutic applications. These materials change configuration post-implantation, adapting to anatomical structures or triggering drug release [67].

5.4.2. Programmable Materials

Development of materials with programmable degradation profiles allows temporal control over drug release and tissue regeneration. These systems respond to specific biological triggers, enabling precise therapeutic interventions [68].

5.5. Sustainable Manufacturing

5.5.1. Green Chemistry

Implementation of environmentally friendly production methods reduces toxic waste and energy consumption. New polymer synthesis routes utilize renewable resources and minimize harmful byproducts [69].

5.5.2. Recycling and Biodegradation

Advanced recycling technologies enable the recovery and reuse of polymer materials while maintaining pharmaceutical grade quality. Optimization of biodegradation pathways ensures complete material breakdown without harmful environmental impacts [70].

5.6. Digital Health

5.6.1. IoT-Enabled Devices

Integration of sensors and communication systems within printed devices enables remote monitoring of drug delivery and patient response. These smart systems provide real-time data for healthcare providers to optimize treatment protocols [71].

5.6.2. Personalized Medicine Platforms

Development of digital platforms that combine patient data, imaging, and 3D printing capabilities streamline the production of personalized therapeutic devices. These systems enable rapid customization and manufacturing of patient-specific treatments [72].

6. Challenges and Limitations

6.1. Regulatory Compliance

6.1.1. Quality Control Standards

The implementation of Good Manufacturing Practice (GMP) standards for 3D-printed pharmaceutical products presents unique challenges. The variability inherent in personalized manufacturing processes requires robust quality control measures and validation protocols [73]. Documentation requirements for patient-specific products necessitate new approaches to batch definition and testing procedures [74].

Table 4. Quality Control Parameters for 3D-Printed Drug Delivery Systems

Parameter	Test Method	Acceptance Criteria	Critical Factors
Content uniformity	HPLC/UV	RSD ≤ 6%	Drug distribution
Dimensional accuracy	Digital imaging	± 5%	Printer calibration
Mechanical strength	Compression testing	Product specific	Material properties
Drug release profile	Dissolution testing	Q-value ± 10%	Matrix structure
Surface quality	SEM/profilometry	Ra < 5 μm	Print parameters

6.1.2. Safety Assessment

Long-term safety evaluation of 3D-printed biodegradable devices requires comprehensive studies examining degradation products, tissue responses, and potential toxicity. The complexity of these systems, particularly those incorporating multiple materials or active pharmaceutical ingredients, demands extensive characterization and biological assessment [75].

6.2. Manufacturing Challenges

6.2.1. Scalability Issues

The transition from laboratory-scale production to commercial manufacturing faces significant hurdles. Current printing technologies often lack the throughput necessary for large-scale production, while maintaining the precision required for medical devices [76]. The need for specialized equipment and controlled environments increases production costs and complexity [77].

Table 5. Manufacturing Requirements

Aspect	Requirements	Challenges	Potential Solutions
GMP compliance	Clean room facilities	Cost intensive	Modular facilities
Process validation	Three consecutive batches	Time consuming	PAT implementation
Documentation	Complete batch records	Complex process	Digital documentation
Quality control	In-process controls	Multiple parameters	Automated testing
Stability testing	ICH guidelines	Long duration	Predictive modeling

6.2.2. Process Validation

Establishing consistent manufacturing processes across different production sites and equipment presents significant challenges. Variables such as environmental conditions, material batch variations, and equipment specifications must be carefully controlled and validated [78].

6.3. Material Limitations

6.3.1. Thermal Stability

The processing temperatures required for certain 3D printing techniques can compromise drug stability and polymer properties. The narrow processing window available for thermally sensitive materials restricts the range of applicable drugs and excipients [79].

6.3.2. Mechanical Properties

Achieving optimal mechanical properties while maintaining drug delivery functionality remains challenging. The incorporation of active pharmaceutical ingredients often affects the mechanical integrity of printed structures, requiring careful balance between drug loading and structural requirements [80].



Figure 4. Degradation Mechanisms and Environmental Factors

6.4. Clinical Implementation

6.4.1. Cost Considerations

The economic viability of personalized 3D-printed drug delivery systems faces challenges related to production costs, specialized equipment requirements, and skilled personnel needs. The development of cost-effective manufacturing processes while maintaining product quality remains crucial [81].

6.4.2. Healthcare Integration

Integration of 3D printing technology into existing healthcare systems requires significant infrastructure development and personnel training. The establishment of standardized protocols for patient assessment, design optimization, and product manufacturing presents logistical challenges [82].

6.5. Technical Limitations

6.5.1. Resolution Constraints

Current printing technologies face limitations in achieving microscale features while maintaining structural integrity. The resolution requirements for certain medical applications exceed the capabilities of available printing systems [83].

6.5.2. Material Processing

The development of printable formulations that maintain both processability and therapeutic efficacy presents ongoing challenges. Issues such as material degradation during processing and inconsistent drug distribution require continued research attention [84].

6.6. Stability and Storage

6.6.1. Product Stability

Long-term stability of 3D-printed drug delivery systems, particularly under varying environmental conditions, requires careful consideration. The potential for physical and chemical changes during storage necessitates comprehensive stability testing protocols [85].

6.6.2. Storage Requirements

Special storage conditions may be required to maintain product integrity, particularly for personalized medications. The development of appropriate packaging and storage guidelines presents additional challenges [86].

7. Conclusion

The 3D printing technology with biodegradable polymers marks a significant advancement in personalized medicine, offering better solutions for drug delivery and tissue engineering applications. The ability to fabricate patient-specific devices with precise control over geometry, drug distribution, and release kinetics represents a paradigm shift in therapeutic interventions. Biodegradable polymers, particularly PLA, PCL, and PLGA, serve as versatile materials for creating sophisticated drug delivery systems through various 3D printing techniques. Smart materials, hybrid composites, and stimuli-responsive systems have further expanded the capabilities of these technologies. Advanced manufacturing methods, including multi-material printing and precision control systems, enable the creation of complex therapeutic devices with enhanced functionality. The successful implementation of artificial intelligence and machine learning algorithms in process optimization and quality control demonstrates the potential for improved manufacturing efficiency and product consistency. Integration with digital health platforms and IoT technology facilitates real-time monitoring and adjustment of therapeutic interventions, advancing the field toward truly personalized medicine. The optimization of material properties, printing processes, and quality control measures remains crucial for widespread clinical adoption. Additionally, the development of cost-effective manufacturing approaches and standardized protocols will be essential for commercial viability.

References

[1] Kang HW, Lee SJ, Ko IK, Kengla C, Yoo JJ, Atala A. A 3D bioprinting system to produce human-scale tissue constructs with structural integrity. Nat Biotechnol. 2016;34(3):312-9.

[2] Zhang B, Gao L, Ma L, Luo Y, Yang H, Cui Z. 3D bioprinting: A novel avenue for manufacturing tissues and organs. Engineering. 2019;5(4):777-94.

[3] Tyler B, Gullotti D, Mangraviti A, Utsuki T, Brem H. Polylactic acid (PLA) controlled delivery carriers for biomedical applications. Adv Drug Deliv Rev. 2016;107:163-75.

[4] Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3(3):1377-97.

[5] Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116(4):2602-63.

[6] Murphy SV, Atala A. 3D bioprinting of tissues and organs. Nat Biotechnol. 2014;32(8):773-85.

[7] Ligon SC, Liska R, Stampfl J, Gurr M, Mülhaupt R. Polymers for 3D printing and customized additive manufacturing. Chem Rev. 2017;117(15):10212-90.

[8] Wang X, Jiang M, Zhou Z, Gou J, Hui D. 3D printing of polymer matrix composites: A review and prospective. Compos Part B Eng. 2017;110:442-58.

[9] Norman J, Madurawe RD, Moore CM, Khan MA, Khairuzzaman A. A new chapter in pharmaceutical manufacturing: 3D-printed drug products. Adv Drug Deliv Rev. 2017;108:39-50.

[10] Mao M, He J, Li X, Zhang B, Lei Q, Liu Y, et al. The emerging frontiers and applications of high-resolution 3D printing. Micromachines. 2017;8(4):113.

[11] Awad A, Trenfield SJ, Goyanes A, Gaisford S, Basit AW. Reshaping drug development using 3D printing. Drug Discov Today. 2018;23(8):1547-55.

[12] Gao B, Yang Q, Zhao X, Jin G, Ma Y, Xu F. 4D bioprinting for biomedical applications. Trends Biotechnol. 2016;34(9):746-56.

[13] Chia HN, Wu BM. Recent advances in 3D printing of biomaterials. J Biol Eng. 2015;9:4.

[14] Jamróz W, Szafraniec J, Kurek M, Jachowicz R. 3D printing in pharmaceutical and medical applications. Pharm Res. 2018;35(9):176.

[15] Goole J, Amighi K. 3D printing in pharmaceutics: A new tool for designing customized drug delivery systems. Int J Pharm. 2016;499(1-2):376-94.

[16] Liu J, Sun L, Xu W, Wang Q, Yu S, Sun J. Current advances and future perspectives of 3D printing natural-derived biopolymers. Carbohydr Polym. 2019;207:297-316.

[17] Moroni L, Burdick JA, Highley C, Lee SJ, Morimoto Y, Takeuchi S, et al. Biofabrication strategies for 3D in vitro models and regenerative medicine. Nat Rev Mater. 2018;3(5):21-37.

[18] Tian H, Tang Z, Zhuang X, Chen X, Jing X. Biodegradable synthetic polymers: Preparation, functionalization and biomedical application. Prog Polym Sci. 2012;37(2):237-80.

[19] Park K. Controlled drug delivery systems: Past forward and future back. J Control Release. 2014;190:3-8.

[20] Alhnan MA, Okwuosa TC, Sadia M, Wan KW, Ahmed W, Arafat B. Emergence of 3D printed dosage forms: Opportunities and challenges. Pharm Res. 2016;33(8):1817-32.

[21] Hutmacher DW, Schantz T, Zein I, Ng KW, Teoh SH, Tan KC. Mechanical properties and cell cultural response of polycaprolactone scaffolds designed and fabricated via fused deposition modeling. J Biomed Mater Res. 2001;55(2):203-16.

[22] Pan Z, Ding J. Poly(lactide-co-glycolide) porous scaffolds for tissue engineering and regenerative medicine. Interface Focus. 2012;2(3):366-77.

[23] Zhou X, Hou Y, Lin J. A review on the processing accuracy of two-photon polymerization. AIP Advances. 2015;5(3):030701.

[24] Khademhosseini A, Langer R. A decade of progress in tissue engineering. Nat Protoc. 2016;11(10):1775-81.

[25] Kumar N, Jain AK, Singh C, Kumar R. Development, characterization and solubility study of solid dispersion of terbinafine hydrochloride by solvent evaporation method. Asian J Pharm. 2008;2(2):154-8.

[26] Zadpoor AA, Malda J. Additive manufacturing of biomaterials, tissues, and organs. Ann Biomed Eng. 2017;45(1):1-11.

[27] Zhang Y, Yu Y, Ozbolat IT. Direct bioprinting of vessel-like tubular microfluidic channels. J Nanotechnol Eng Med. 2013;4(2):020902.

[28] Middleton JC, Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. Biomaterials. 2000;21(23):2335-46.

[29] Goyanes A, Det-Amornrat U, Wang J, Basit AW, Gaisford S. 3D scanning and 3D printing as innovative technologies for fabricating personalized topical drug delivery systems. J Control Release. 2016;234:41-8.

[30] Melocchi A, Parietti F, Maroni A, Foppoli A, Gazzaniga A, Zema L. Hot-melt extruded filaments based on pharmaceutical grade polymers for 3D printing by fused deposition modeling. Int J Pharm. 2016;509(1-2):255-63.

[31] Zhang J, Feng X, Patil H, Tiwari RV, Repka MA. Coupling 3D printing with hot-melt extrusion to produce controlled-release tablets. Int J Pharm. 2017;519(1-2):186-97.

[32] Khaled SA, Burley JC, Alexander MR, Roberts CJ. Desktop 3D printing of controlled release pharmaceutical bilayer tablets. Int J Pharm. 2014;461(1-2):105-11.

[33] Wang X, Ao Q, Tian X, Fan J, Wei Y, Hou W, et al. 3D bioprinting technologies for hard tissue and organ engineering. Materials. 2016;9(10):802.

[34] Melchels FPW, Feijen J, Grijpma DW. A review on stereolithography and its applications in biomedical engineering. Biomaterials. 2010;31(24):6121-30.

[35] Do AV, Khorsand B, Geary SM, Salem AK. 3D printing of scaffolds for tissue regeneration applications. Adv Healthc Mater. 2015;4(12):1742-62.

[36] Fina F, Goyanes A, Gaisford S, Basit AW. Selective laser sintering (SLS) 3D printing of medicines. Int J Pharm. 2017;529(1-2):285-93.

[37] Shirazi SFS, Gharehkhani S, Mehrali M, Yarmand H, Metselaar HSC, Adib Kadri N, et al. A review on powder-based additive manufacturing for tissue engineering: selective laser sintering and inkjet 3D printing. Sci Technol Adv Mater. 2015;16(3):033502.

[38] Yang Y, Wang G, Liang H, Gao C, Peng S, Shen L, et al. Additive manufacturing of bone scaffolds. Int J Bioprint. 2019;5(1):148.

[39] Cui X, Boland T, D'Lima DD, Lotz MK. Thermal inkjet printing in tissue engineering and regenerative medicine. Recent Pat Drug Deliv Formul. 2012;6(2):149-55.

[40] Derby B. Inkjet printing of functional and structural materials: fluid property requirements, feature stability, and resolution. Annu Rev Mater Res. 2010;40:395-414.

[41] Daly R, Harrington TS, Martin GD, Hutchings IM. Inkjet printing for pharmaceutics - A review of research and manufacturing. Int J Pharm. 2015;494(2):554-67.

[42] Ozbolat IT, Hospodiuk M. Current advances and future perspectives in extrusion-based bioprinting. Biomaterials. 2016;76:321-43.

[43] Gungor-Ozkerim PS, Inci I, Zhang YS, Khademhosseini A, Dokmeci MR. Bioinks for 3D bioprinting: an overview. Biomater Sci. 2018;6(5):915-46.

[44] Heinrich MA, Liu W, Jimenez A, Yang J, Akpek A, Liu X, et al. 3D Bioprinting: from Benches to Translational Applications. Small. 2019;15(23):1805510.

[45] Sun Y, Soh S. Printing tablets with fully customizable release profiles for personalized medicine. Adv Mater. 2015;27(47):7847-53.

[46] Park JH, Jang J, Lee JS, Cho DW. Three-dimensional printing of tissue/organ analogues containing living cells. Ann Biomed Eng. 2017;45(1):180-94.

[47] Wang X, Xu S, Zhou S, Xu W, Leary M, Choong P, et al. Topological design and additive manufacturing of porous metals for bone scaffolds and orthopaedic implants: A review. Biomaterials. 2016;83:127-41.

[48] Bose S, Vahabzadeh S, Bandyopadhyay A. Bone tissue engineering using 3D printing. Mater Today. 2013;16(12):496-504.

[49] Holländer J, Genina N, Jukarainen H, Khajeheian M, Rosling A, Mäkilä E, et al. Three-dimensional printed PCL-based implantable prototypes of medical devices for controlled drug delivery. J Pharm Sci. 2016;105(9):2665-76.

[50] Khaled SA, Burley JC, Alexander MR, Yang J, Roberts CJ. 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. J Control Release. 2015;217:308-14.

[51] Trenfield SJ, Awad A, Goyanes A, Gaisford S, Basit AW. 3D printing pharmaceuticals: drug development to frontline care. Trends Pharmacol Sci. 2018;39(5):440-51.

[52] Zhang B, Seong B, Nguyen V, Byun D. 3D printing of high-resolution PLA-based structures by hybrid electrohydrodynamic and fused deposition modeling techniques. J Micromech Microeng. 2016;26(2):025015.

[53] Pere CPP, Economidou SN, Lall G, Ziraud C, Boateng JS, Alexander BD, et al. 3D printed microneedles for insulin skin delivery. Int J Pharm. 2018;544(2):425-32.

[54] Lim SH, Ng JY, Kang L. Three-dimensional printing of a microneedle array on personalized curved surfaces for dual-pronged treatment of trigger finger. Biofabrication. 2017;9(1):015010.

[55] Yi HG, Choi YJ, Kang KS, Hong JM, Pati RG, Park MN, et al. A 3D-printed local drug delivery patch for pancreatic cancer growth suppression. J Control Release. 2016;238:231-41.

[56] Sun Y, Ruan X, Li H, Kathuria H, Du G, Kang L. Fabrication of non-dissolving analgesic suppositories using 3D printed moulds. Int J Pharm. 2016;513(1-2):717-24.

[57] Zhang Y, Kumar P, Lv S, Di X, Zhao H, Cai Z, et al. Recent advances in 3D bioprinting for the development of in vitro tumor models. Acta Biomater. 2021;128:1-28.

[58] Mele M, Heredia-Guerrero JA, Bayer IS, Ciofani G, Genchi GG, Ceseracciu L, et al. 3D printing of stimuli-responsive polymers: Present and future perspectives in drug delivery. Pharmaceutics. 2021;13(9):1407.

[59] Lee JY, An J, Chua CK. Fundamentals and applications of 3D printing for novel materials. Appl Mater Today. 2017;7:120-33.

[60] Shin S, Kim H, Rim T, Lee JY. Recent advances in smart therapeutics using 3D printing technology. Pharmaceutics. 2021;13(6):912.

[61] Zhu W, Ma X, Gou M, Mei D, Zhang K, Chen S. 3D printing of functional biomaterials for tissue engineering. Curr Opin Biotechnol. 2016;40:103-12.

[62] Agarwal T, Chiesa I, Presutti D, Irawan V, Vajanthri KY, Costantini M, et al. Recent advances in bioprinting technologies for engineering different cartilage-based tissues. Mater Sci Eng C. 2021;123:112005.

[63] Wu Q, Therriault D, Heuzey MC. Processing and properties of chitosan inks for 3D printing of hydrogel microstructures. ACS Biomater Sci Eng. 2018;4(7):2643-52.

[64] Raquez JM, Habibi Y, Murariu M, Dubois P. Polylactide (PLA)-based nanocomposites. Prog Polym Sci. 2013;38(10-11):1504-42.

[65] Guo T, Holzberg TR, Lim CG, Gao F, Gargava A, Trachtenberg JE, et al. 3D printing PLGA: a quantitative examination of the effects of polymer composition and printing parameters on print resolution. Biofabrication. 2017;9(2):024101.

[66] Jiang T, Munguia-Lopez JG, Flores-Torres S, Grant J, Vijayakumar S, Leon-Rodriguez A, et al. Directing the self-assembly of tumour spheroids by bioprinting cellular heterogeneous models within alginate/collagen hydrogels. Sci Rep. 2017;7(1):4575.

[67] Zhang B, Cristescu R, Chrisey DB, Narayan RJ. A review of recent developments in 4D bioprinting. Int J Bioprint. 2020;6(4):267.

[68] Nadgorny M, Ameli A. Functional polymers and nanocomposites for 3D printing of smart structures and devices. ACS Appl Mater Interfaces. 2018;10(21):17489-507.

[69] Ding S, Feng L, Wu J, Zhu F, Tan H. Biomedical soft materials for 3D printing. Bio-Des Manuf. 2021;4(4):741-62.

[70] Cardoso VF, Francesko A, Ribeiro C, Bañobre-López M, Martins P, Lanceros-Mendez S. Advances in magnetic nanoparticles for biomedical applications. Adv Healthc Mater. 2018;7(5):1700845.

[71] Mitsouras D, Liacouras P, Imanzadeh A, Giannopoulos AA, Cai T, Kumamaru KK, et al. Medical 3D printing for the radiologist. Radiographics. 2015;35(7):1965-88.

[72] Alhnan MA, Okwuosa TC, Sadia M, Wan KW, Ahmed W, Arafat B. Emergence of 3D printed dosage forms: Opportunities and challenges. Pharm Res. 2016;33(8):1817-32.

[73] Awad A, Trenfield SJ, Gaisford S, Basit AW. 3D printed medicines: A new branch of digital healthcare. Int J Pharm. 2018;548(1):586-96.

[74] Alomari M, Mohamed FH, Basit AW, Gaisford S. Personalised dosing: Printing a dose of one's own medicine. Int J Pharm. 2015;494(2):568-77.

[75] Palo M, Holländer J, Suominen J, Yliruusi J, Sandler N. 3D printed drug delivery devices: perspectives and technical challenges. Expert Rev Med Devices. 2017;14(9):685-96.

[76] Ventola CL. Medical applications for 3D printing: Current and projected uses. P T. 2014;39(10):704-11.

[77] Afshar M, Afshar M, Shafaghi B, Ghanbari H. Challenges and opportunities in 3D bioprinting of tissues. Artif Cells Nanomed Biotechnol. 2016;44(6):1401-11.

[78] Yao R, Xu G, Mao SS, Yang HY, Sang XT, Sun W, et al. Three-dimensional printing: review of application in medicine and hepatic surgery. Cancer Biol Med. 2016;13(4):443-51.

[79] Lee JY, Tan WS, An J, Chua CK, Tang CY, Fane AG, et al. The potential to enhance membrane module design with 3D printing technology. J Membr Sci. 2016;499:480-90.

[80] Gopinathan J, Noh I. Recent trends in bioinks for 3D printing. Biomater Res. 2018;22:11

[81] Ligon SC, Liska R, Stampfl J, Gurr M, Mülhaupt R. Polymers for 3D printing and customized additive manufacturing. Chem Rev. 2017;117(15):10212-90.

[82] Tappa K, Jammalamadaka U. Novel biomaterials used in medical 3D printing techniques. J Funct Biomater. 2018;9(1):17.

[83] Hospodiuk M, Dey M, Sosnoski D, Ozbolat IT. The bioink: A comprehensive review on bioprintable materials. Biotechnol Adv. 2017;35(2):217-39.

[84] Ning L, Chen X. A brief review of extrusion-based tissue scaffold bio-printing. Biotechnol J. 2017;12(8):1600671.

[85] Seirin-Lee S, Genovese F, Tosin M. Mathematical models of 3D bioprinting: From design to implementation. Math Biosci Eng. 2020;17(4):3601-29.

[86] Kang HW, Lee SJ, Ko IK, Kengla C, Yoo JJ, Atala A. A 3D bioprinting system to produce human-scale tissue constructs with structural integrity. Nat Biotechnol. 2016;34(3):312-9

Author's short biography

Mr. Ramprasad D. Kadam

Mr. Ramprasad D. Kadam is a research scholar in the Department of Pharmaceutics at IVM's Krishnarao Bhegade Institute of Pharmaceutical Education and Research. His research focuses on novel drug delivery systems and formulation development of oral solid dosage forms, with particular emphasis on improving bioavailability of poorly soluble drugs

Dr. Amol S. Rakte

Dr. Amol S. Rakte serves as Professor and Head of the Department of Pharmaceutics at IVM's Krishnarao Bhegade Institute of Pharmaceutical Education and Research. He has contributed significantly to the field through numerous publications and research collaborations in controlled release technologies with extensive experience in pharmaceutical formulation and drug delivery systems,

Mr. Mangesh M. Galbale

Mangesh M. Galbale is pursuing research in pharmaceutics at IVM's Krishnarao Bhegade Institute of Pharmaceutical Education and Research, focusing on the development of novel drug delivery systems and optimization of pharmaceutical formulations. His work involves innovative methods in targeted drug delivery

Mr. Swaraj S. Warkad

Swaraj S. Warkad is a research scholar at IVM's Krishnarao Bhegade Institute of Pharmaceutical Education and Research, specializing in advanced drug delivery systems. His research interests include the development of modified release formulations and enhancement of drug bioavailability through novel formulation strategies.